ArticleInfectious diseases and therapy2024

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

Dipak R Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.